Stereotaxis Stock News

Zacks Investment Research cut shares of Stereotaxis (NYSEAMERICAN:STXS) from a hold rating to a strong sell rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospitals interventional surgical suite to enhance the treatment of coronary artery []

Related Stocks: COWN , GEF.B , STXS , WRK , LEN.B , CIT , JXN , SPNT , REVH , SPNT , NODK , KKR ,

Stereotaxis (NYSEAMERICAN:STXS) was downgraded by Zacks Investment Research from a hold rating to a strong sell rating in a report released on Wednesday, Zacks.com reports. According to Zacks, Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospitals interventional surgical suite to enhance the treatment of coronary artery disease []

ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include presentations of the companys innovation pipeline by members of Stereotaxis leadership with a live Q&A session.

ST. LOUIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system, advancing electrophysiology patient care and expanding access to advanced robotic technology for the treatment of cardiac arrhythmias in the greater St. Louis region.

Stereotaxis (NYSEAMERICAN:STXS) posted its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter, missing analysts consensus estimates of ($0.04) by ($0.03), MarketWatch Earnings reports. Stereotaxis had a negative return on equity of 24.21% and a negative net margin of 25.42%. Shares of STXS stock opened at $6.52 on Friday. Stereotaxis has []

The stock price of Stereotaxis Inc (NYSEAMERICAN: STXS) increased by 20.5% today. This is why it happened.

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2021 Results - Earnings Call Transcript

ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will relea

ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of it

The stock price of Stereotaxis Inc (NYSEAMERICAN: STXS) has seen an uptick this week. This is why it happened.

ST. LOUIS, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fische

Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2021 Results - Earnings Call Transcript

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 33.33% and 10.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of